alexa Have FDA Expedited Programs Really Shortened Drug Review Time? An Analysis Of Newly Approved Therapies And How FDA Expedited Programs Have Impacted Drug Development Timelines
ISSN: 2167-7689

Pharmaceutical Regulatory Affairs: Open Access
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

4th International Conference on Pharmaceutical Regulatory Affairs
September 08-10, 2014 DoubleTree by Hilton Hotel Raleigh-Brownstone-University, USA

Krasimira Pekova
ScientificTracks Abstracts: Pharmaceut Reg Affairs
DOI: 10.4172/2167-7689.S1.014
Abstract
In attempt to encourage innovative drug development, the FDA has developed four approaches to expedite the drug approval process. These four approaches include Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review. Fast Track was introduced to accelerate the approval of medications for serious conditions and to fulfill unmet medical need. Accelerated Approval is a pathway that permits medications for serious conditions that fulfill unmet medical need to receive approval based on a surrogate endpoint. Priority Review is designated for medications that when they get approved they will bring significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions when compared to standard applications. Breakthrough therapy designation is anovel pathway introduced in 2012. Breakthrough therapy designation is process intended to treat serious or life threatening disease and the approved drug may demonstrate significant advantage over the available therapies. The objective of the research was to identify which of the expedited programs shorten development time and which products and classes benefit the most. It was analyzed new molecular entities that have been approved over the last 6 years (2009-2014). The entities were categorized by therapeutic area, line of therapy and mechanism-specific order of entry. Then it was evaluated whether the new entities had utilized one or more of the expedited programs, and whether the expedited program shortened the time from IND to regulatory approval.
Biography
Krasimira Pekova is a licensed pharmacist with extensive experience in the healthcare industry in Europe and United States. She holds a pharmacy degree from Bulgaria and Master of Science in Regulatory Affairs of Drugs, Biologics and Medical Devices from Northeastern University, Boston. She is an Analyst with Artisan Healthcare Consulting, where she provides market access insights to global brands. She analyses the oncology global market access repository, a compilation of regulatory, health technology assessment, and reimbursement decisions for oncology products in the 15 largest markets worldwide.
image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords